The FDA indication for tesamorelin is excess abdominal fat in adults with HIV and lipodystrophy. The older study often cited for sermorelin used a modified GHRH analog in 19 adults. These studies cannot tell you how the two drugs compare for fat loss, muscle gain or anti-aging.

Correction, November 15, 2026. The earlier version treated a modified GHRH analog as evidence for sermorelin itself and described the study as a four-month comparison. The authors describe four weeks of placebo followed by 16 weeks of the analog. This update also clarifies the FDA indication and Geref history.

What the tesamorelin trials measured

In a 26-week trial, 412 adults with HIV and excess abdominal fat were randomized to subcutaneous tesamorelin or placebo. CT-measured visceral fat decreased by 15.2% in the tesamorelin group and increased by 5.0% with placebo. These were group-level changes in visceral fat. [1]

The FDA prescribing information for EGRIFTA WR specifies reduction of excess abdominal fat in adults with HIV and lipodystrophy. The label excludes weight-loss management. It also says long-term cardiovascular safety has not been established and that the WR and SV formulations are not substitutable.

A separate 12-month study enrolled 61 adults with HIV and fatty liver disease. It tested subcutaneous tesamorelin against placebo. The estimated difference in liver fat fraction was 4.1 percentage points lower with tesamorelin. Liver fat is a separate outcome from visceral abdominal fat, and this study does not establish an approved use for fatty liver disease. [2]

What the older GHRH study measured

The 1997 report studied 19 adults aged 55 to 71. The author abstract describes four weeks of subcutaneous placebo followed by 16 weeks of subcutaneous [Nle27]GHRH(1-29)-NH2. That is a modified GHRH analog. The methods described in the abstract do not provide a separate parallel group receiving placebo throughout the treatment period. [3]

Nocturnal growth hormone and circulating IGF-1 increased during the analog period. The authors also measured body composition and reported a lean-mass increase in men only, with no change in body weight in either sex. These small-sample findings apply to the tested analog and do not establish what commercial sermorelin would do. [3]

The FDA record for Geref

The FDA notice describes historical approvals for Geref sermorelin acetate injection for diagnosis of growth hormone deficiency and treatment of growth failure in children with idiopathic growth hormone deficiency. The two approvals were withdrawn in 2009. In 2013, the FDA determined that the products had been withdrawn from sale for reasons other than safety or effectiveness. These historical approvals did not cover adult anti-aging or body composition.

What current research could answer

A 2026 trial protocol plans to compare tesamorelin plus exercise with placebo plus the same exercise program in 100 adults aged 50 to 80 with HIV, excess abdominal adiposity and frailty or pre-frailty. It describes physical-function and muscle outcomes without reporting results. It does not include sermorelin.

The studies above compare different products, in different populations, on different outcomes. They do not establish which drug works better or is safer for body composition in adults without HIV.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified clinician for individual medical decisions.

References

  1. Metabolic effects of a growth hormone-releasing factor in patients with HIV.. The New England journal of medicine, 2007.
  2. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.. The lancet. HIV, 2019.
  3. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.. The Journal of clinical endocrinology and metabolism, 1997.